Prognostic awareness in older adults with metastatic cancer: Secondary analysis of a randomized controlled trial.

C Cristiane Decat Bergerot (Oncoclinicas&Co - Medica Scientia Innovation Research (MEDSIR), Sao Paulo, Brazil) P Paulo Gustavo Bergerot (Oncoclinicas&Co - Medica Scientia Innovation Research (MEDSIR), Sao Paulo, Brazil) M Marianne Razavi (City of Hope Comprehensive Cancer Center, Duarte, CA) M Marcos V.S. Franca (Rede D’Or, Brasilia, Brazil) J Jonas Ribeiro Gomes Silva (Oncoclinicas&Co - Medica Scientia Innovation Research (MEDSIR), Sao Paulo, Brazil) J Jose Adolfo Cerveira (Oncoclinicas&Co - Medica Scientia Innovation Research (MEDSIR), Sao Paulo, Brazil) W William Hiromi Fuzita (Oncoclinicas&Co - Medica Scientia Innovation Research (MEDSIR), Sao Paulo, Brazil) G Gabriel Marques dos Anjos (Oncoclínicas&Co - Medica Scientia Innovation Research (MEDSIR), Sao Paulo, Brazil) R Renata Ferrari (Oncoclinicas&Co - Medica Scientia Innovation Research (MEDSIR), Sao Paulo, Brazil) S Sarah Ananda Gomes (Oncoclinicas & Co - Medica Scientia Innovation Research (MEDSIR), Sao Paulo, Brazil) E Errol James Philip (University of California Los Angeles, Los Angeles, CA) M Murilo Buso (Oncoclinicas&Co - Medica Scientia Innovation Research (MEDSIR), Sao Paulo, Brazil) M Mariana Laloni (Oncoclinicas&Co - Medica Scientia Innovation Research (MEDSIR), Sao Paulo, Brazil) C Carlos Gil Ferreira (Oncoclinicas&Co - Medica Scientia Innovation Research (MEDSIR), Sao Paulo, Brazil) S Sumanta Kumar Pal (Department of Medical Oncology City of Hope Comprehensive Cancer Center Duarte California USA) R Ryan David Nipp (Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK) A Areej El-Jawahri (1Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA) E Enrique Soto Pérez de Celis (National Institute of Medical Sciences and Nutrition Salvador Zubirán, Mexico City, Mexico) W William Dale (City of Hope National Medical Center, Duarte, CA)

Abstract

1624 Background: Prognostic awareness plays a key role in patient outcomes, particularly among older adults with metastatic cancer. This secondary analysis of a randomized controlled trial (RCT) evaluated the effect of a Geriatric Assessment-guided Intervention (GAIN-S) on patient responses to prognosis items over time between two arms. Methods: Eligible participants, aged 65+, diagnosed with metastatic solid cancers, and undergoing treatment across multiple Brazilian states, were randomized 1:1 into two arms. The GAIN-S included a geriatric assessment (GA), which devised tailored treatment based on identified impairments. Patients in the usual care (UC) arm received standard care. Both arms completed the Illness and Prognostic Awareness Impact Questionnaire (PAIS) at baseline (T1) and 12 weeks (T2), assessing Emotional (10 items; range 0-30) and Adaptive (12 items; range 0-36) domains; each rated on a 4-point Likert scale The change in PAIS (T2 - T1) was calculated for each participant in both the GAIN-S and UC arms, and then the mean changes in PAIS between the two arms were compared via independent t-test. Results: Eighty-six patients were approached; 80 provided consent (93% enrollment rate). At 12 weeks, the analytic sample included 77 patients. Demographic characteristics were well-balanced between arms, with a mean age of 74.5 years (SD=6.1), primarily female (55.8%), self-identified as White (71.4%), and 50.4% had at least a college education. The most common cancer types were genitourinary (29.9%), breast (24.7%), and gastrointestinal (22.1%). At T1, no significant differences were noted in PAIS between arms. However, there was significant improvement in PAIS Emotional (UC: mean change=-0.26, SD=1.6 vs GAIN-S: mean change=0.87, SD=1.4; P=0.002) and Adaptive (UC: mean change=-0.07, SD=0.6 vs GAIN-S: mean change=0.74, SD=1.7; P=0.008) domains between in the GAIN-S arm (Table). Conclusions: This secondary analysis highlights the impact of GA-guided care on improving prognostic awareness in older adults with metastatic cancer. GAIN-S resulted in significant improvements in Emotional and Adaptive domains compared to UC. Tailored interventions addressing the specific needs of older adults with metastatic cancer may enhance understanding of prognosis and improve adaptive responses. Studies are needed to determine whether these differences translate into meaningful improvements in outcomes. Impact of GAIN-S intervention on prognostic awareness. Change over time Arm 1 (T2-T1)Mean (SD) Arm 2 (T2-T1)Mean (SD) DifferenceArm 2 - Arm 1 (SE) p-value Emotional Domain10 items (range: 0-30) -0.263 (1.62) 0.872 (1.44) 1.135 (0.35) 0.002 Adaptive Domain12 items (range: 0-36) -0.079 (0.67) 0.744 (1.73) 0.823 (0.30) 0.008

Article Details

Volume / Issue Vol. 43, Issue 16_suppl
Published June 01, 2025
Pages 1624-1624
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (19)

C

Cristiane Decat Bergerot

Oncoclinicas&Co - Medica Scientia Innovation Research (MEDSIR), Sao Paulo, Brazil

P

Paulo Gustavo Bergerot

Oncoclinicas&Co - Medica Scientia Innovation Research (MEDSIR), Sao Paulo, Brazil

M

Marianne Razavi

City of Hope Comprehensive Cancer Center, Duarte, CA

M

Marcos V.S. Franca

Rede D’Or, Brasilia, Brazil

J

Jonas Ribeiro Gomes Silva

Oncoclinicas&Co - Medica Scientia Innovation Research (MEDSIR), Sao Paulo, Brazil

J

Jose Adolfo Cerveira

Oncoclinicas&Co - Medica Scientia Innovation Research (MEDSIR), Sao Paulo, Brazil

W

William Hiromi Fuzita

Oncoclinicas&Co - Medica Scientia Innovation Research (MEDSIR), Sao Paulo, Brazil

G

Gabriel Marques dos Anjos

Oncoclínicas&Co - Medica Scientia Innovation Research (MEDSIR), Sao Paulo, Brazil

R

Renata Ferrari

Oncoclinicas&Co - Medica Scientia Innovation Research (MEDSIR), Sao Paulo, Brazil

S

Sarah Ananda Gomes

Oncoclinicas & Co - Medica Scientia Innovation Research (MEDSIR), Sao Paulo, Brazil

E

Errol James Philip

University of California Los Angeles, Los Angeles, CA

M

Murilo Buso

Oncoclinicas&Co - Medica Scientia Innovation Research (MEDSIR), Sao Paulo, Brazil

M

Mariana Laloni

Oncoclinicas&Co - Medica Scientia Innovation Research (MEDSIR), Sao Paulo, Brazil

C

Carlos Gil Ferreira

Oncoclinicas&Co - Medica Scientia Innovation Research (MEDSIR), Sao Paulo, Brazil

S

Sumanta Kumar Pal

Department of Medical Oncology City of Hope Comprehensive Cancer Center Duarte California USA

R

Ryan David Nipp

Stephenson Cancer Center, The University of Oklahoma Health Sciences Center, Oklahoma City, OK

A

Areej El-Jawahri

1Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA

E

Enrique Soto Pérez de Celis

National Institute of Medical Sciences and Nutrition Salvador Zubirán, Mexico City, Mexico

W

William Dale

City of Hope National Medical Center, Duarte, CA